Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.
Health Minister Roberto Speranza visited the Italian IRBM yesterday. The company is collaborating on the clinical trials with the University of Oxford. “Only a safe, effective vaccine can take us out of the emergency – says Speranza – for this reason Italy’s role is relevant in the European deal signed recently. We are proud of our scientists and of the excellence of Italian research.”
Article published on il Giornale – 19/06/2020